CC
GILD icon

Centiva Capital’s Gilead Sciences GILD Stock Holding History

Centiva Capital’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.34M Hold
10,600
– – 0.01% 522
2026
Q1 		$1.48M Buy
10,600
+600
+6% +$84K 0.01% 501
2025
Q4 		$1.23M Buy
+10,000
New +$1.22M 0.01% 522
2025
Q1 		– Sell
-5,700
Closed -$527K – 1756
2024
Q4 		$527K Sell
5,700
-10,000
-64% -$900K 0.01% 793
2024
Q3 		$1.32M Buy
15,700
+10,000
+175% +$763K 0.03% 688
2024
Q2 		$391K Hold
5,700
– – 0.01% 1311
2024
Q1 		$418K Sell
5,700
-4,300
-43% -$331K 0.01% 1081
2023
Q4 		$810K Sell
10,000
-6,100
-38% -$475K 0.02% 713
2023
Q3 		$1.21M Buy
16,100
+6,100
+61% +$469K 0.03% 549
2023
Q2 		$771K Sell
10,000
-10,000
-50% -$798K 0.02% 661
2023
Q1 		$1.66M Sell
20,000
-30,000
-60% -$2.48M 0.04% 461
2022
Q4 		$4.29M Hold
50,000
– – 0.12% 178
2022
Q3 		$3.08M Sell
50,000
-200
-0.4% -$12.6K 0.06% 247
2022
Q2 		$3.1M Sell
50,200
-19,500
-28% -$1.21M 0.07% 240
2022
Q1 		$4.14M Sell
69,700
-121,200
-63% -$7.75M 0.08% 217
2021
Q4 		$13.9M Buy
190,900
+190,230
+28,393% +$13.1M 0.29% 61
2021
Q3 		$47K Sell
670
-29,330
-98% -$2.06M ﹤0.01% 1133
2021
Q2 		$2.07M Buy
+30,000
New +$2M 0.05% 316
2021
Q1 		– Sell
-8,300
Closed -$483K – 1242
2020
Q4 		$483K Sell
8,300
-13,100
-61% -$790K 0.02% 472
2020
Q3 		$1.35M Buy
21,400
+8,800
+70% +$610K 0.09% 160
2020
Q2 		$969K Buy
12,600
+5,800
+85% +$444K 0.06% 182
2020
Q1 		$508K Sell
6,800
-97,800
-93% -$6.76M 0.02% 308
2019
Q4 		$6.8M Buy
104,600
+55,200
+112% +$3.59M 0.33% 63
2019
Q3 		$3.13M Buy
49,400
+7,100
+17% +$464K 0.19% 107
2019
Q2 		$2.86M Sell
42,300
-46,800
-53% -$3.08M 0.17% 110
2019
Q1 		$5.79M Buy
89,100
+11,700
+15% +$778K 0.39% 39
2018
Q4 		$4.84M Buy
77,400
+3,000
+4% +$210K 0.38% 45
2018
Q3 		$5.75M Buy
+74,400
New +$5.62M 0.5% 30

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Centiva Capital's GILD Position: Q2 2026 in Review

Centiva Capital increased its Gilead Sciences (GILD) stake by 79% in Q2 2026, buying an estimated $171K and bringing the position to 2,953 shares worth $373K. The position accounts for ﹤0.01% of the portfolio, ranked #1060.

Centiva Capital first reported a position in GILD in Q1 2018 and has held it in 27 quarters since. The position peaked at $6.01M in Q1 2023. 2,291 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Centiva Capital held 2,953 shares of Gilead Sciences worth $373K as of Q2 2026.
  • Centiva Capital bought 1,301 Gilead Sciences shares in Q2 2026, an estimated $171K.
  • Gilead Sciences made up ﹤0.01% of Centiva Capital's portfolio in Q2 2026, its #1060 holding.
  • Centiva Capital first reported a position in Gilead Sciences in Q1 2018 and has held it in 27 quarters since.
  • Centiva Capital's Gilead Sciences position peaked at $6.01M in Q1 2023.
  • 2,291 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Centiva Capital's 13F filing for Q2 2026, filed 13 Aug 2026.